Pulmonary arterial hypertension (PAH) is a devastating and rapidly progressing disease that induces substantial pulmonary vascular remodeling. The pathologic changes especially in pulmonary microvasculature result in progressive increases in the mean pulmonary artery pressure and pulmonary vascular resistance, which, if untreated leads to right-ventricular failure and death. Although it is clear that PAH has a multifactorial pathobiology, recent discoveries pointed out crucial role of Transforming Growth Factor (TGF)-beta family members in the pathophysiology of PAH. The TGF-beta superfamily is composed of multifunctional mediators, including the TGF-beta isoforms and the Bone Morphogenetic Proteins (BMPs). Germline mutations in the gene coding for BMP receptor 2 (BMPR2) have been identifi ed in 60% of familial and 10-30% of idiopathic PAH. Mutations in the TGF-beta receptors, ALK-1 and endoglin, have been found in PAH patients with a personal or family history of hereditary hemorrhagic telangiectasia. Non-canonical TGF-beta pathways as well as TGF-beta receptor ligands (i.e. BMP9) are also involved in PAH development. Our improved understanding of TGF-beta pathway regulation will have important implications for the development of novel therapeutic strategies for this complex and serious disease. Animal models will undoubtedly have an important role in this process; however human studies will give the fi nal answer about the effi cacy and safety of the novel treatments for PAH. This review provides an overview of the TGF-beta and BMPs potential role in PAH.
Pulmonary arterial hypertension (PAH) is either due to cardiac, pulmonary or extrathoracic disorders (secondary PAH) or without any detectable cause (primary or idiopathic PAH; IPAH). 1 In some cases, primary PAH occurs in young patients with a mitochondrial disorder, 2 but whether there is a causal relation between them, remains to be elucidated. Regardless of the etiology, unrelieved pulmonary hypertension advance to right-sided heart failure, progressive debilitation and death, often within 2 to 3 years after its initial diagnosis. Lung specimens from patients with PAH and from experimental models underline the importance of vascular cell proliferation and obliteration of small pulmonary arteries by smooth muscle cells and myofi broblasts in the pathogenesis of this disease. In addition, plexiform lesions comprising endothelial cells and myofi broblasts are found in about 50% of cases.
Over the last decade, some major advances have led to substantial improvements in the management of PAH. Much of this progress was pioneered by work in animal models. Although none of the current animal models of PAH completely recapitulate the human disease, they do provide insight into the cellular pathways contributing to its development and progression. Genetic studies have revealed heterozygous mutations in the BMPR2 gene encoding the type II bone morphogenetic protein receptor (Bmpr2), a member of the TGF-beta superfamily of receptors, underlying the familial form of the disease. 3 Subsequently, BMPR2 mutations were found in about 25% of apparently sporadic cases of IPAH, many of which are examples of familial transmission with low disease gene penetrance. These studies pointed toward a critical role for the TGFbeta superfamily in the pathogenesis of PAH through the molecular mechanisms that include regulation of pulmonary vascular cell growth and differentiation. 4
TGF-beta signalling pathways
TGF-beta superfamily has over 35 structurally related pleiotropic cytokines that also includes TGF-beta1, TGF-beta3, Activins, Nodals and bone morphogenetic proteins (BMPs). Signalling by TGF-beta family members occurs through type II serine/threonine kinase receptors and type I receptors, also termed Activin-receptor-like kinases (ALKs). 5 Each member of the TGF-beta superfamily binds to a characteristic combination of type I and type II receptors. Ligand binding induces the assembly of type I and type II receptors into complexes, within which type II phosphorylates type I receptor and this phosphorylation is both essential and suffi cient for TGF-beta signalling ( Figure 1 ). Endoglin, an accessory receptor, modulates TGF-beta signaling by regulating surface TGF-beta receptors and their activation. 6 Once activated, the type I receptor can induce several signaling outcomes which include phosphorylation of cytoplasmic proteins called regulatory Smads (Smad2/3 or Smad1/5/8) that trimerize with Smad4 leading to nuclear shuttling and gene transcription regulation. In addition, non-Smad signaling pathways can also be induced ( Figure 1 ) including members of the mitogen activated protein kinase (MAPK) pathway, JNK, p38, p42/44 (ERK), PI3-kinase and Rho pathways. 7 Involvement of non-Smad pathways in pathogenesis of PAH is well known, especially the ras homolog family member A (RhoA)-Rho kinase (ROCK) axis which specifi c inhibition is currently the most promising therapeutic approach for PAH. 8 Also, it was recently reported that BMPR2 defi ciency promotes pro-proliferative and anti-apoptotic responses in pulmonary arterial smooth muscle cells through the activation of TGFâ-TAK1-MAPK pathways in PAH. 9
TGF-beta receptor mutations in PAH
Although mutations in the BMPR2 gene are the most frequent germline mutations identifi ed in familial (~60%) and idiopathic PAH (10-30%), they are absent in some families and in the majority of sporadic and associated cases of PAH. This fact led to the investigation of other gene involvement from TGF-beta family in PAH. Indeed, mutations in the TGF-beta receptors, ALK-1 and endoglin, have been identifi ed in PAH patients with a personal or family history of hereditary hemorrhagic telangiectasia (HHT). 10 It is important to stress out that TGF-beta signalling is essential for regulation of vasculogenesis and angiogenesis. Mutations in at least fi ve genes result in HHT (Rendu Osler-Weber-syndrome), an autosomal dominant disorder with a prevalence of about 1 in 5-8,000 individuals, but mutations in two genes (Endoglin, ENG causing HHT1 and ALK1 causing HHT2) account for approximately 85% of cases. HHT is characterized by epistaxis, mucocutaneous and gastrointestinal telangiectases and arteriovenous malformations (AVMs) in pulmonary, hepatic and cerebral circulation. 11 Defi ciency in endoglin or Alk1 causes cardiovascular defects leading to embryonic lethality. Mouse heterozygous models for HHT1 and HHT2 has been developed allowing further insight in the role of TGF-beta family in blood vessel and heart development and vascular homeostasis. 12, 13 Our and other studies have revealed a marked defi ciency in nitric oxide (NO) mediated vasodilation in endoglin-haploinsuffi cient mice (Eng +/-), as well as that endoglin has an important role in endothelial NO synthase (eNOS) activation. 14, 15 Moreover, endoglin and Alk1 associate with and stabilize the eNOS activation complex leading to NO production. In heterozygous conditions for either endoglin or Alk1, eNOS becomes uncoupled and produces more superoxide than NO which leads to tissue damage and impaired vascular tone control. Interestingly, our recent work also revealed that adult Eng and Alk1 heterozygous mice have signs of pulmonary arterial hypertension including increased right ventricular (RV) systolic pressure, RV hypertrophy, degeneration of the distal pulmonary vasculature, and muscularization of small arteries. PAH that heterozygous mice develop is attributable to uncoupled eNOS activity and increased superoxide (•O 2 ) production, which can be prevented by antioxidant treatment. 16, 17 On the other hand, Bmpr2 heterozygous mice had no or mildly elevated pulmonary pressure. 18, 19 However, the infusion of serotonin caused several signs of PAH in Bmpr2 +/mice, further increased by hypoxic conditions.
Authors showed that BMPR2 haploinsuffi ciency increased susceptibility to PAH and pulmonary vascular remodeling in vivo providing a link between two key systems widely implicated in the pathogenesis of PAH. 19 Also, a transgenic dominant-negative form of Bmpr2 specifi cally expressed and activated after birth in smooth muscle cells led to increased pulmonary arterial pressure suggesting that the mutation need to be expressed in smooth muscle to produce the phenotype. 20 More recently, Hong et al. have used conditional knockout mice in which BMPR2 gene was deleted in pulmonary endothelial cells. They showed that endothelial BMPR2 deletion is in itself not suffi cient to cause PAH but can increase the susceptibility to PAH. 21 It is therefore clear that PAH is very complex disease with initial stages likely involving the interaction between genetic predisposition (i.e. BMPR2, ALK1, and ENG mutations) and environmental risk factors. Genetic mutations of TGFbeta family members are not suffi cient to induce PAH, but are serious predisposing factors. To add even more complexity to the topic, mutations of SMAD4 (common Smad; Figure 1 ) do not predispose to PAH, but are seen in patients with juvenile polyposis (JP), colorectal cancer, and with the combined syndrome of JP and HHT (JP-HHT). 22 Finally, one report showed patient with BMPR2 mutation exibiting PAH with HHT features, particularly pulmonary AVMs. 23 That pointed out the possibility that PAH and HHT have a common molecular pathogenesis.
Not only the TGF-beta family receptors but also their ligands could have important role in PAH pathobiology. The recent fi nding of circulating BMP9 as the true physiological ligand for ALK1, acting in combination with Bmpr2 (Figure 1) , supports a role for BMP9 in PAH. Endoglin potentiates the effects of BMP9 and can therefore affect these pathways. Moreover, BMP9 can stimulate endothelin 1 (ET-1) release from pulmonary endothelial cells. 24 ET-1 involvements in the pathogenesis of PAH is well known and endothelin receptor antagonists have been a therapeutic mainstay in PAH, providing benefi t to many patients. 25
Epilogue TGF-beta superfamily has a critical role in the development and maintenance of the pulmonary vasculature. Genetic defects and imbalance of TGF-beta and BMP pathways contribute signifi cantly to the development of pulmonary arterial hypertension. Pharmacological approach and identifi cation of small inhibitory molecules to these pathways will allow modulation of the TGF-beta superfamily signaling and assist in development of future therapeutics for PAH.
However, the complex regulation of these pathways and their involvement in many fundamental biological processes such as cell growth, differentiation, embryonic de-velopment and tissue homeostasis, may raise many safety issues and slow the pace of progress. Nevertheless, our growing knowledge of the TGF-beta pathway regulation should teach us how to restore the balance that is lost in patients with PAH. It should assure the progress in this fi eld and open new avenues and possibilities of gene replacement therapy and personalized medicine in the treatment of this life threatening disease.
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